Compare ADNT & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | SANA |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | ADNT | SANA |
|---|---|---|
| Price | $19.00 | $5.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $21.90 | $7.83 |
| AVG Volume (30 Days) | 1.2M | ★ 5.4M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,535,000,000.00 | N/A |
| Revenue This Year | $1.36 | N/A |
| Revenue Next Year | $2.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.04 | $1.26 |
| 52 Week High | $26.16 | $7.30 |
| Indicator | ADNT | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 59.30 |
| Support Level | $18.69 | $4.25 |
| Resistance Level | $19.37 | $5.36 |
| Average True Range (ATR) | 0.61 | 0.52 |
| MACD | 0.14 | 0.11 |
| Stochastic Oscillator | 33.41 | 77.95 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.